P1- HIGH VIRAL SUPPRESSION AND IMPROVED SAFETY PROFILE OF TENOFOVIR ALAFENAMIDE RELATIVE TO TENOFOVIR DISOPROXIL FUMARATE IN CHRONIC HEPATITIS B PATIENTS TREATED FOR 5 YEARS
Introduction and Objectives: Tenofovir Alafenamide (TAF) is a preferred treatment in the most recent EASL and AASLD HBV Guidelines, especially in patients with risk factors for TDF-associated renal and bone effects. In 2 identically-designed double-blind (DB), randomized (2:1), Phase 3 studies (HBeA...
Na minha lista:
| Principais autores: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2023-03-01
|
| coleção: | Annals of Hepatology |
| Acesso em linha: | http://www.sciencedirect.com/science/article/pii/S1665268123000091 |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|
